Physician profile
Christopher L Rucker
NPI 1114115581
$10,136.18
in general payments reported to CMS, 2019-2025
45 companies · $956 in 2025
The $956 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $1,069 · 2021: $1,636 · 2022: $1,773 · 2023: $1,838 · 2024: $1,762 · 2025: $956.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,555.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,321.99 | 2020-2025 | Qulipta, Ubrelvy, Vraylar |
| Novo Nordisk INC | $1,115.65 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $1,112.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $894.66 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $893.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $734.81 | 2019-2025 | |
| Amgen INC. | $528.85 | 2019-2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $499.83 | 2019-2024 | Jardiance, Ofev |
| Novartis Pharmaceuticals Corporation | $242.68 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $233.77 | 2019-2025 | Capvaxive, Gardasil 9, Gardasil |
| Bayer Healthcare Pharmaceuticals INC. | $227.32 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $174.60 | 2023-2025 | Gvoke Hypopen |
| Otsuka America Pharmaceutical, INC. | $167.29 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $148.63 | 2019-2022 | |
| Amarin Pharma, INC. | $140.89 | 2019-2022 |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Rucker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.